Literature DB >> 6232467

Reticulo-endothelial function in glomerulonephritis.

L R Solomon, V I Rawlinson, S Howarth, N P Mallick.   

Abstract

IgG- and C3b-coated erythrocytes were used to investigate splenic Fc-receptor function and hepatic C3b-receptor function by measurements of their blood clearance. Most patients with glomerular disease including those who were HLA, A1, B8, DR3 had normal Fc-receptor function. Occasional individuals with persistent glomerulonephritis had delayed clearance unrelated to disease activity. In rapidly progressive glomerulonephritis, the phenomenon of 'reticulo-endothelial blockade' was confirmed. C3b-receptor function was normal in most patients with persistent glomerulonephritis. A defect in splenic Fc-receptor function hepatic C3b-receptor function is unlikely to underlie persistent glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232467     DOI: 10.1159/000183208

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Prolonged circulation of immune complexes due to various altered immune functions contributes to nephritis in MRL/lpr mice.

Authors:  N A Granholm; T Cavallo
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  A transient monocyte defective function in idiopathic nephrotic syndrome (lipoid nephrosis).

Authors:  A Branellec; J Laurent; J M Heslan; C Bruneau; G Lagrue
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

3.  Kinetic analysis of the blood clearance and organ uptake curves of IgG-coated red cells in HLA-typed controls and patients with Wegener's granulomatosis.

Authors:  F J van der Woude; H Beekhuis; J M Beelen; T H The
Journal:  Eur J Nucl Med       Date:  1986

4.  Mononuclear phagocyte system Fc-receptor function in patients with seropositive rheumatoid arthritis.

Authors:  S Lobatto; F C Breedveld; J A Camps; E K Pauwels; M L Westedt; M R Daha; L A van Es
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.